Lancet oncol:全球癌症患儿的5年存活率!

2019-05-25 QQ MedSci原创

癌症患儿存活率的精准评估对决策者和临床医生制定治疗方案至关重要。但很多国家都缺乏观察性的存活率评估,即使有,结果差异也很大。现研究人员对全球癌症患儿的存活率进行评估,同时评估对儿童癌症预后影响的多种因素。研究人员开发了一个微模拟模型来模拟全球200个国家和地区的癌症患儿存活率,包括临床和流行病学因素,特定国家的治疗变量,如化疗、放疗和手术的可用性。采用该模型对每个国家和地区儿童癌症确诊病例的5年净

癌症患儿存活率的精准评估对决策者和临床医生制定治疗方案至关重要。但很多国家都缺乏观察性的存活率评估,即使有,结果差异也很大。现研究人员对全球癌症患儿的存活率进行评估,同时评估对儿童癌症预后影响的多种因素。

研究人员开发了一个微模拟模型来模拟全球200个国家和地区的癌症患儿存活率,包括临床流行病学因素,特定国家的治疗变量,如化疗、放疗和手术的可用性。采用该模型对每个国家和地区儿童癌症确诊病例的5年净存活率和七项旨在改善治疗的干预措施的潜在存活效益进行评估。

结果:全球儿童癌症确诊病例的5年净存活率为37.4%(95% CI 34.7-39.8);地区差异很大,非洲东部的存活率仅8.1%(4.4-13.7),而北美可达83.0%(81.6-84.4)。对于七项干预措施,单一收益甚微,使5年净存活率增加至38.4%(35.8-40.9)-44.6%(41.7-47.4)。当将政策干预措施捆绑到改善服务提供的一系列措施中时,5年净生存期(50.2%[47.3-53.0])显著增加;政策干预措施与增加治疗可及性相结合时,5年净存活率可增加至54.1%(50.1-58.5%)。所有干预措施组成的综合的系统方法时显著提高存活效益,5年净存活率可提高到80.8%(79.5-82.1)。

癌症患儿的存活率随地区的不同差异很大,非洲东部的存活率尤为的低。虽然增加治疗可及性和财务负担至关重要,但在卫生系统和设施层面提高护理质量的投资也是该善全球癌症患儿预后所必需的。

原始出处:

Zachary J Ward,et al. Global childhood cancer survival estimates and priority-setting: a simulation-based analysis. The Lancet Oncology. May 22, 2019. https://doi.org/10.1016/S1470-2045(19)30273-6

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1800047, encodeId=4171180004e39, content=<a href='/topic/show?id=8293e13551a' target=_blank style='color:#2F92EE;'>#癌症患儿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71355, encryptionId=8293e13551a, topicName=癌症患儿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sat Jan 04 04:29:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830086, encodeId=9523183008681, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 07 22:29:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865656, encodeId=2b0f1865656d0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 30 11:29:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862946, encodeId=b8cf186294648, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Mar 18 14:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1800047, encodeId=4171180004e39, content=<a href='/topic/show?id=8293e13551a' target=_blank style='color:#2F92EE;'>#癌症患儿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71355, encryptionId=8293e13551a, topicName=癌症患儿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sat Jan 04 04:29:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830086, encodeId=9523183008681, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 07 22:29:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865656, encodeId=2b0f1865656d0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 30 11:29:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862946, encodeId=b8cf186294648, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Mar 18 14:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=)]
    2020-01-07 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1800047, encodeId=4171180004e39, content=<a href='/topic/show?id=8293e13551a' target=_blank style='color:#2F92EE;'>#癌症患儿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71355, encryptionId=8293e13551a, topicName=癌症患儿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sat Jan 04 04:29:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830086, encodeId=9523183008681, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 07 22:29:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865656, encodeId=2b0f1865656d0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 30 11:29:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862946, encodeId=b8cf186294648, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Mar 18 14:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=)]
    2019-05-30 minlingfeng
  4. [GetPortalCommentsPageByObjectIdResponse(id=1800047, encodeId=4171180004e39, content=<a href='/topic/show?id=8293e13551a' target=_blank style='color:#2F92EE;'>#癌症患儿#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71355, encryptionId=8293e13551a, topicName=癌症患儿)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/6F20312C71B4B22F603078C6DCFA72CE/100, createdBy=d3572500071, createdName=ms306040998833292, createdTime=Sat Jan 04 04:29:00 CST 2020, time=2020-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1830086, encodeId=9523183008681, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Tue Jan 07 22:29:00 CST 2020, time=2020-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1865656, encodeId=2b0f1865656d0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Thu May 30 11:29:00 CST 2019, time=2019-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862946, encodeId=b8cf186294648, content=<a href='/topic/show?id=b5ca453451f' target=_blank style='color:#2F92EE;'>#存活率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45345, encryptionId=b5ca453451f, topicName=存活率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b3f89, createdName=daviiliu, createdTime=Wed Mar 18 14:29:00 CST 2020, time=2020-03-18, status=1, ipAttribution=)]

相关资讯

PNAS:破解PD-1抗体促进癌症超进展之谜!日本科学家发现PD-1抗体可激活调节T细胞,导致癌症超进展

之前的一项研究数据显示,多癌种的晚期患者中,9%(12/131)在PD-1单抗治疗期间死于HPD。此前我们报道的韩国研究则显示,晚期非小细胞肺癌患者中HPD发生的比例为18.9%。

Journal of Diabetes:糖尿病可能致多种癌症风险升高

长期以来,人们一直猜测糖尿病和癌症之间存在某种关联,但之前各类报告的研究结果往往不一致。中国的一项新研究显示,2型糖尿病可能导致多种癌症的患病风险升高,其中包括涉及男性的11种癌症和涉及女性的13种癌症。

膳食纤维+益生菌 竟能限制癌症进展?

饮食能对肠道微生物群产生显着影响。通过复杂的代谢相互作用,良好的饮食习惯有助于预防癌症。更具体地说,富含纤维的饮食可降低患特定癌症的风险,如结直肠癌(CRC)。虽然饮食是预防癌症的有效手段,但其在癌症进展和治疗中的作用仍鲜为人知。最近,卢森堡系统生物医学中心和卢森堡大学生命科学研究中心的研究团队发现,益生元(如膳食纤维)和益生菌(特定有益细菌)的组合,可降低原癌基因和耐药基因的表达。这种组合会导致

J Thromb Haemost:全血细胞计数、d-二聚体和可溶性P-选择素与癌症患者动脉血栓栓塞风险的关联

由此可见,绝对中性粒细胞计数升高和sP-选择素水平升高与癌症患者ATE风险增加有关。它们在预测癌症相关ATE中的作用需要在进一步的研究来验证。

1例癌症晚期重度疼痛患者的药学监护

疼痛已成为癌症患者最常见的伴随症状。有报道,初诊癌症患者的疼痛发生率为25%;晚期癌症患者的疼痛发生率约为60%~80%,其中1/3患者为重度疼痛。目前止痛治疗已成为癌症晚期姑息治疗很重要的一部分。在由医生、药师和护士组成的疼痛治疗团队中,临床药师发挥了非常重要的作用。本文通过临床药师参与1例肺癌晚期患者的止痛治疗,说明临床药师在药学监护及药物不良反应监测方面发挥的作用。